IMS Therapy Report Neurodegenerative Disease IMS THERAPY REPORT Neurodegenerative Disease 2005 IMS Health Incorporated or its affiliates. All rights reserved. Neurodegenerative Disease IMS Therapy Report
NW1 6JB, UK Tel: +44 (0)20 7393 5888, Fax: +44 (0)20 7393 5346 service@imshealth.com http://www.imshealth.com The Information Service contained herein is confidential and provided subject to the IMS Health Information Services Standard Terms and Conditions. This Information Service is provided to the client on a personal basis under a non-exclusive and non-transferable licence for the Client’s own direct benefit and use only, and may not be copied or divulged to any other party. Whilst every possible care has been taken in the preparation of this information, the publishers do not
hold themselves responsible for any expressions of opinion or error or omission, or any action resulting there from. 2005 IMS Health Incorporated or its affiliates. All rights reserved.
2005 IMS Health Incorporated or its affiliates. All rights reserved. IMS Therapy Report Neurodegenerative Disease Table of Contents DATA DEFINITIONS AND SOURCES Sales Data and Exchange Rates Other Sources Manufacturers and Brands IMS Health The MIDAS Database System EXECUTIVE SUMMARY Neurodegenerative Disease Market Key Findings Anti-Alzheimer Products Market Key Findings Anti-Parkinson Products Market Key Findings The Threat of NDD Treatment The Global Market
Anti-Alzheimer Products Market by Region
Anti-Parkinson Products Market by Region
Late-stage R&D The Future
The Future of the Anti-Alzheimer Products Market
The Future of the Anti-Parkinson Products Market
2005 IMS Health Incorporated or its affiliates. All rights reserved. Neurodegenerative Disease IMS Therapy Report 1.0 DISEASE OVERVIEW 1.1 Definition of Neurodegenerative Disease
1.1.2 Alzheimer’s Disease and Down’s Syndrome
1.1.3 Parkinson’s Disease and Parkinsonism
1.1.7 Consequences of Neurodegenerative Disease
1.2 Diagnosis & Treatment
1.2.1 Diagnosis and Treatment of Alzheimer’s Disease
1.2.2 Diagnosis and Treatment of Parkinson’s Disease and Parkinsonism
1.2.3 Diagnosis and Treatment of Other Neurodegenerative Diseases
1.3 The Costs of Neurodegenerative Disease
1.3.1 The Cost-effectiveness of NDD Products
2.0 EPIDEMIOLOGY 2.1 Neurological Care Resources 2.2 The Global Burden of Neurodegenerative Diseases
2.2.1 Impact of Alzheimer’s Disease on Mortality and Life Expectancy
2.2.2 Impact of Parkinson’s Disease on Mortality and Life Expectancy
3.0 NEURODEGENERATIVE DISEASE DRUG CLASSES 3.1 Global Drug Classes 3.2 Definition of Anti-Alzheimer Drug Sub-classes 3.3 Definition of Anti-Parkinson Drug Sub-classes 2005 IMS Health Incorporated or its affiliates. All rights reserved. IMS Therapy Report Neurodegenerative Disease 4.0 LEADING PRODUCTS IN THE GLOBAL MARKET 4.1 Global Product Sales
4.1.1 Leading Global Anti-Alzheimer Products
4.1.2 Top 20 Global Anti-Parkinson Products
4.2 Anti-Alzheimer Product Profiles 4.3 Anti-Parkinson Product Profiles 5.0 LEADING GLOBAL MANUFACTURERS 5.1 Global Neurodegenerative Disease Product Manufacturer Sales 5.2 Global Anti-Alzheimer Product Manufacturer Sales
5.2.1 Total Global Sales by Manufacturer
5.3 Global Anti-Parkinson Product Manufacturer Sales
5.3.1 Total Global Sales by Manufacturer
5.4 Sales Comparisons of the Leading NDD Manufacturers
5.4.1 Sales Comparison of Leading Anti-Alzheimer Product Manufacturers
5.4.2 Sales Comparison of Leading Anti-Parkinson Product Manufacturers
5.5 Profiles of the Leading Manufacturers 2005 IMS Health Incorporated or its affiliates. All rights reserved. Neurodegenerative Disease IMS Therapy Report 6.0 OVERVIEW OF NATIONAL MARKETS FOR NEURODEGENERATIVE DISEASE PRODUCTS 6.1 Neurodegenerative Disease Product Sales in Selected Markets 6.2 Anti-Alzheimer Product Sales in Selected Markets
6.2.1 Comparison of Anti-Alzheimer Product Sales in Selected Markets
6.2.2 Anti-Alzheimer Product Sales as a Proportion of National Pharmaceutical Markets
6.3 Anti-Parkinson Product Sales in Selected Markets
6.3.1 Comparison of Anti-Parkinson Product Sales in Selected Markets
6.3.2 Anti-Parkinson Product Sales as a Proportion of National Pharmaceutical Markets
7.0 THE BRAZILIAN MARKET 7.1 Pharmaceutical Market Background 7.2 The Brazilian Anti-Alzheimer Products Market 7.3 The Brazilian Anti-Parkinson Products Market 8.0 THE CANADIAN MARKET 8.1 Pharmaceutical Market Background 8.2 The Canadian Anti-Alzheimer Products Market 8.3 The Canadian Anti-Parkinson Products Market 9.0 THE FRENCH MARKET 9.1 Pharmaceutical Market Background 9.2 The French Anti-Alzheimer Products Market 9.3 The French Anti-Parkinson Products Market 2005 IMS Health Incorporated or its affiliates. All rights reserved. IMS Therapy Report Neurodegenerative Disease 10.0 THE GERMAN MARKET 10.1 Pharmaceutical Market Background 10.2 The German Anti-Alzheimer Products Market 10.3 The German Anti-Parkinson Products Market 11.0 THE ITALIAN MARKET 11.1 Pharmaceutical Market Background 11.2 The Italian Anti-Alzheimer Products Market 11.3 The Italian Anti-Parkinson Products Market 12.0 THE JAPANESE MARKET 12.1 Pharmaceutical Market Background 12.2 The Japanese Anti-Alzheimer Products Market 12.3 The Japanese Anti-Parkinson Products Market 13.0 THE MEXICAN MARKET 13.1 Pharmaceutical Market Background 13.2 The Mexican Anti-Alzheimer Products Market 13.3 The Mexican Anti-Parkinson Products Market 2005 IMS Health Incorporated or its affiliates. All rights reserved. Neurodegenerative Disease IMS Therapy Report 14.0 THE SPANISH MARKET 14.1 Pharmaceutical Market Background 14.2 The Spanish Anti-Alzheimer Products Market 14.3 The Spanish Anti-Parkinson Products Market 15.0 THE UK MARKET 15.1 Pharmaceutical Market Background 15.2 The UK Anti-Alzheimer Products Market 15.3 The UK Anti-Parkinson Products Market 16.0 THE US MARKET 16.1 Pharmaceutical Market Background 16.2 The US Anti-Alzheimer Products Market 16.3 The US Anti-Parkinson Products Market 17.0 RESEARCH & DEVELOPMENT 17.1 Anti-Alzheimer Products in Development
17.1.1 Profiles of Leading Anti-Alzheimer Products in Development
17.2 Anti-Parkinson Products in Development
17.2.1 Profiles of Leading Anti-Parkinson Products in Development
18.0 THE FUTURE OF NEURODEGENERATIVE DISEASE TREATMENTS MARKETS 18.1 Aggregate Event-based Forecasts 18.2 Canada 2005 IMS Health Incorporated or its affiliates. All rights reserved. IMS Therapy Report Neurodegenerative Disease
18.2.1 Diagnosis and Prescribing Profiles
18.2.3 The Future of the Canadian Anti-Alzheimer Products Market
18.2.4 The Future of the Canadian Anti-Parkinson Products Market
18.3 France
18.3.1 Diagnosis and Prescribing Profiles
18.3.3 The Future of the French Anti-Alzheimer Products Market
18.3.4 The Future of the French Anti-Parkinson Products Market
18.4 Germany
18.4.1 Diagnosis and Prescribing Profiles
18.4.3 The Future of the German Anti-Alzheimer Products Market
18.4.4 The Future of the German Anti-Parkinson Products Market
18.5 Italy
18.5.1 Diagnosis and Prescribing Profiles
18.5.3 The Future of the Italian Anti-Alzheimer Products Market
18.5.4 The Future of the Italian Anti-Parkinson Products Market
18.6 Japan
18.6.1 Diagnosis and Prescribing Profiles
18.6.3 The Future of the Japanese Anti-Alzheimer Products Market
18.6.4 The Future of the Japanese Anti-Parkinson Products Market
18.7 Spain
18.7.1 Diagnosis and Prescribing Profiles
18.7.3 The Future of the Spanish Anti-Alzheimer Products Market
18.7.4 The Future of the Spanish Anti-Parkinson Products Market
18.8 The UK
18.8.1 Diagnosis and Prescribing Profiles
18.8.3 The Future of the UK Anti-Alzheimer Products Market
18.8.4 The Future of the UK Anti-Parkinson Products Market
18.9 The US
18.9.1 Diagnosis and Prescribing Profiles
18.9.3 The Future of the US Anti-Alzheimer Products Market
18.9.4 The Future of the US Anti-Parkinson Products Market
18.10 The Future of the Global Neurodegenerative Disease Products Markets
18.10.1 The Future of the Global Anti-Alzheimer Products Market
18.10.2 The Future of the Global Anti-Parkinson Products Market
2005 IMS Health Incorporated or its affiliates. All rights reserved. Neurodegenerative Disease IMS Therapy Report 19.0 OPINIONS ON THE FUTURE OF THE NEURODEGENERATIVE DISEASE PRODUCTS MARKET 19.1 NICE Committee Holds Key to Development of UK Anti-Alzheimer Products Market 19.2 What is the Future of Parkinson’s Patient Care in the UK? 19.3 The Challenges and Holy Grails of Alzheimer’s research 19.4 Future Pricing Trends in the EU Market for Neurodegenerative Disease Products 19.5 The Future of the US Neurodegenerative Disease Products Markets 19.6 The Current and Future State of Parkinson’s Disease Care in the US 2005 IMS Health Incorporated or its affiliates. All rights reserved.
ROBERT KEVIN BLACKBURN EXPERIENCE Mass Spectrometry Laboratory Supervisor (Feb 2007 – Present) Molecular and Structural Biochemistry, North Carolina State University, Raleigh, NC Investigator (April 2001 – December 2006) Disease and Biomarker Proteomics, GlaxoSmithKline, Inc., Research Triangle Park, NC Research Scientist (August 1994-March 2001) Department of St
The report goes on to say that chiropractors “allied themselves with the Red Cross initially in order to maintain access to the facility, but they were able to offer The April 19, 2004 issue of the Journal of a specific skill, which even if not planned for in advance, Vertebral Subluxation Research provides us with an seemed useful to those who already had access.” interesting artic